Skip to main content
. 2022 Mar 27;14(4):720. doi: 10.3390/pharmaceutics14040720

Figure 2.

Figure 2

Radioluminescent images at various time points after the intravenous injection of 177Lu2O3-iPSMA (13 MBq, 0.1 mg) in healthy CD1 mice.